The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy.
Prior studies have shown that intravitreal daunorubicin (9-15 nmol) and triamcinolone acetonide (2 mg) are effective individually in preventing retinal detachment in experimental proliferative vitreoretinopathy. This report compares the efficacy of the combination of daunorubicin (15 nmol) and triamcinolone acetonide (2 mg) with that of daunorubicin alone in a refined experimental model of proliferative vitreoretinopathy. The degree of retinal detachment in each treatment group was graded, with the unequivocal absence or presence of retinal detachment used as an indicator of treatment success or failure. Both treatments (daunorubicin alone and in combination with triamcinolone acetonide) effectively prevented retinal detachment. However, there was no significant difference in the rate of retinal detachment between the two treatment groups. These results indicate that combination therapy with daunorubicin/triamcinolone is no more effective at preventing retinal detachment than daunorubicin alone.
Chen
E P
EP
Department of Ophthalmology, Duke University, Durham, North Carolina.
Steinhorst
U H
UH
Samsa
G P
GP
Saloupis
P T
PT
Hatchell
D L
DL
D000818:Animals; D003630:Daunorubicin / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005128:Eye Diseases / Q000188:drug therapy; D005260:Female; D005347:Fibroblasts; D005654:Fundus Oculi; D008297:Male; D011817:Rabbits; D011897:Random Allocation; D012163:Retinal Detachment / Q000517:prevention & control*; D012164:Retinal Diseases / Q000188:drug therapy*; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014822:Vitreous Body
D014222:Triamcinolone Acetonide; D003630:Daunorubicin